Etoxidol, 100 mg 20 pcs.

Antioxidant drug

ATX code: C01EB

Pharmacological properties

b>

Pharmacodynamics

Ethoxidol^® is an inhibitor of free radical processes, has membranoprotective, antihypoxic, nootropic, anticonvulsant, anxiolytic action, increases the body’s resistance to stress. Ethoxidol^® has anti-ischemic properties, improves blood flow in ischemic area, limits the zone of ischemic injury, shows hypolipidemic action, reduces the total cholesterol and low-density lipoproteins.

The drug increases resistance of the body to various damaging factors, to oxygen-dependent pathological states (shock, hypoxia and ischemia, cerebral circulatory disorders, intoxication with alcohol and antipsychotic drugs (neuroleptics).

The drug improves cerebral metabolism and blood supply of the brain, improves microcirculation and blood rheological properties, reduces platelet aggregation. It stabilizes membrane structures of blood cells (erythrocytes and platelets) during hemolysis.

The mechanism of action of the drug is caused by its antioxidant, antihypoxant and membrane-protective actions. It inhibits lipid peroxidation, increases superoxidase activity, increases lipid-protein ratio, decreases membrane viscosity and increases its fluidity.

Modulates the activity of membrane-bound enzymes (calcium independent phosphodiesterase, adenylate cyclase, acetylcholinesterase), receptor complexes (benzodiazepine, GABA, acetylcholine), which increases their ability to bind to ligands, helps maintain the structural and functional organization of biomembranes, neurotransport and improve synaptic transmission.

Pharmacokinetics

After oral administration, it is rapidly and completely absorbed from the gastrointestinal tract at an average rate of 0.569±0.086 h^-1. In healthy volunteers, oral administration of Ethoxidol^® tablets at a dose of 100 mg has been shown to achieve maximum concentration (C_max) in plasma reaches 0.28±0.08 hours and is 487.0±72.4 ng/ml followed by rapid drug elimination, with half-life (T_1/2) = 1.46±0.13 hours.

Ethoxidol^® is rapidly distributed throughout the organs and tissues of the body. It is determined in blood plasma for 7-10 hours.

The drug is extensively metabolized in the liver with the formation of phosphate-3-oxypyridine, glucuron-conjugated products.

Indications

– coronary heart disease (as part of complex therapy);

– complex therapy of ischemic stroke;

– dyscirculatory encephalopathy;

– mild to moderate cognitive impairment.

Pharmacological effect

Antioxidant

ATX code: C01EB

Pharmacological properties

Pharmacodynamics

Ethoxidol® is an inhibitor of free radical processes, has membrane protective, antihypoxic, nootropic, anticonvulsant, anxiolytic effects, and increases the body’s resistance to stress. Ethoxidol®
has anti-ischemic properties, improves blood flow in the ischemic zone, limits the area of ​​ischemic damage, exhibits a hypolipidemic effect, reduces the content of total cholesterol and low-density lipoproteins.

The drug increases the body’s resistance to the effects of various damaging factors, to oxygen-dependent pathological conditions (shock, hypoxia and ischemia, cerebrovascular accidents, intoxication with alcohol and antipsychotics (neuroleptics)).

The drug improves cerebral metabolism and blood supply to the brain, improves microcirculation and rheological properties of blood, and reduces platelet aggregation. Stabilizes the membrane structures of blood cells (erythrocytes and platelets) during hemolysis.

The mechanism of action of the drug is due to its antioxidant, antihypoxic and membrane protective effects. It inhibits lipid peroxidation, increases superoxide oxidase activity, increases the lipid-protein ratio, reduces membrane viscosity, and increases its fluidity.

Modulates the activity of membrane-bound enzymes (calcium independent phosphodiesterase, adenylate cyclase, acetylcholinesterase), receptor complexes (benzodiazepine, GABA, acetylcholine), which enhances their ability to bind to ligands, helps preserve the structural and functional organization of biomembranes, neurotransmitter transport and improve synoptic transmission.

Pharmacokinetics

After oral administration, it is quickly and completely absorbed from the gastrointestinal tract at an average rate of 0.569±0.086 h-1. In healthy volunteers, it was found that with oral administration of Ethoxidol® tablets at a dose of 100 mg, the maximum concentration (Cmax) in the blood plasma is reached after 0.28 ± 0.08 hours and is 487.0 ± 72.4 ng/ml, followed by rapid elimination of the drug, with a half-life (T1/2) = 1.46 ± 0.13 hours.

Ethoxidol®
quickly distributed throughout the organs and tissues of the body. Determined in blood plasma for 7-10 hours.

The drug is intensively metabolized in the liver with the formation of phosphate-3-hydroxypyridine and glucurone-conjugated products.

Special instructions

During the treatment period, care must be taken when driving vehicles and engaging in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.

Active ingredient

Ethylmethylhydroxypyridine malate

Composition

One tablet contains:

Active substance:

ethylmethylhydroxypyridine malate (ethoxidol) – 100 mg.

Excipients:

acetylglutamic acid (N-acetyl-L-glutamic acid) – 68 mg,

deanol (2-dimethylaminoethanol) – 32 mg,

glycine – 20 mg,

microcrystalline cellulose – 260.1 mg,

povidone (kollidon 90F) – 1.6 mg,

lactose monohydrate (milk sugar) – 36 mg,

pregelatinized starch (starch 1500) – 30 mg,

colloidal silicon dioxide (Aerosil) – 9.5 mg,

magnesium stearate – 6 mg,

croscarmellose sodium (primellose) – 12.8 mg,

sodium cyclamate – 18 mg,

orange flavor (food flavor “Orange”) – 6 mg.

Pregnancy

Ethoxidol is contraindicated during pregnancy and breastfeeding, since strictly controlled clinical studies of the safety of the drug during pregnancy and lactation have not been conducted.

Contraindications

Hypersensitivity to the components of the drug, lactose intolerance, lactase deficiency, glucose-galactose malabsorption.

Acute liver and/or renal failure, pregnancy, lactation, age under 18 years (efficacy and safety have not been established).

Side Effects

Usually the drug is well tolerated. In rare cases, allergic reactions, dyspeptic disorders, nausea and dry mouth, and diarrhea may occur, which quickly disappear on their own or when the drug is discontinued.

With prolonged use, flatulence and sleep disturbances (drowsiness or difficulty falling asleep) may occur.

Interaction

Enhances the effect of benzodiazepine anxiolytics, anticonvulsants (carbamazepine), antiparkinsonian drugs (levodopa).

Reduces the toxic effects of ethyl alcohol.

Overdose

Due to the low toxicity of the drug, an overdose is unlikely. In case of accidental overdose, symptoms of sleep disturbance may occur – drowsiness, insomnia.

Treatment is symptomatic.

Storage conditions

In a place protected from light at a temperature not exceeding 25°C.

Keep out of the reach of children.

Shelf life

3 years. Do not use after the expiration date stated on the package.

Manufacturer

Sintez, Russia